Getting Mounjaro via GP: the reality behind the assumption

The myth: your GP can just prescribe Mounjaro if you ask

This is the question our prescribers hear most weeks, and the short answer is: sometimes yes, often no, and rarely without a wait. Until April 2026, GPs in England had no NHS route to prescribe tirzepatide for weight management at all, it sat entirely within specialist obesity services. The 2026/27 GP contract changed that, giving practices the ability to prescribe under a new arrangement. But participation is voluntary. Many practices are not yet set up for it, and those that are face a queue of patients who already met the criteria before the contract existed.

The practical upshot: ring your surgery and ask directly. If they're participating, they'll tell you what the wait looks like. If they're not, a referral to a specialist weight management service is the NHS alternative, though waiting times there are also long in most areas. Scotland, Wales and Northern Ireland each run their own eligibility frameworks, which differ from NHS England's phased rollout, so where you live matters a great deal.

For a fuller picture of the GP-prescribing question specifically, the dedicated page on how to get Mounjaro from a GP and what the contract changes mean in practice covers the contract changes in more detail.

Who actually qualifies under NHS criteria right now

NICE's appraisal of tirzepatide (TA1026, published December 2024) set the clinical framework. NHS England translated that into a phased rollout with very specific thresholds. From June 2025, the first cohort covered adults with a BMI of 40 or above plus four or more of five defined conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. From around June 2026, the second cohort opened access to people with a BMI of 35 to 39.9 and four or more of those same conditions.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, 2.5 kg/m² lower across both cohorts. Even so, meeting the numbers on paper does not guarantee prescribing: every patient must also take part in wraparound diet and activity support, and the GP practice still exercises clinical judgement. If you're close to the threshold or uncertain whether your conditions are on the qualifying list, a conversation with your surgery is the right first step rather than assuming you do or don't qualify.

People who don't meet those NHS criteria (or who would rather not wait) can explore what private prescribing involves on the Mounjaro overview page.

What a private prescription route actually involves

Private prescribing of Mounjaro for weight management sits outside the NHS criteria altogether. The licensed eligibility is set by the medicine's authorisation: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, or obstructive sleep apnoea. Those thresholds are broader than the current NHS ones, which is why many people who don't qualify for NHS treatment are clinically suitable for a private prescription.

The process at a GPhC-registered online pharmacy works in a set sequence. You complete a detailed clinical questionnaire. A GPhC-registered Independent Prescriber reads it the same day, a real clinician, not an automated system. Identity is verified with photo ID, and weight is confirmed on a live video call. If clinically suitable, the prescription is issued and the medicine is dispensed from a UK-licensed supply chain. For anyone wondering what a private pharmacy process looks like step by step, the page on getting Mounjaro without a GP referral walks through it clearly.

Cost is a fair question at this point. Since Eli Lilly adjusted UK list prices in September 2025, private Mounjaro typically runs between £149 and £375 per month depending on dose and provider. The Mounjaro cost guide covers what those figures actually include and what to watch for in prices that seem unusually low. Headline prices that exclude clinical assessment, prescription fees, and aftercare support often cost more in practice, and for a prescription medicine, clinical oversight is not an optional add-on.

One practical note: wherever your Mounjaro comes from, the pen needs refrigerating at 2 to 8°C. Most people keep it in the fridge door alongside everyday items, which works fine, just make sure the temperature there stays within range, because the pen's cold-chain matters for the medicine to work as intended. The Patient Information Leaflet that comes with your pen carries the exact storage guidance to follow.

Side effects and safety: the same wherever you're prescribed

Whether a GP, a specialist, or a private prescriber writes the prescription, the medicine and its safety profile are identical. Mounjaro is a dual GIP and GLP-1 receptor agonist, the only one licensed in the UK for weight management. The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping tend to be most noticeable after starting or after a dose increase, usually settling within a couple of weeks as the body adjusts.

More serious but less common concerns include acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update highlighting this for GLP-1 class medicines: severe, persistent abdominal pain (especially if it spreads towards the back) warrants prompt medical attention and should not be waited out. The MHRA Yellow Card scheme allows patients to report suspected side effects directly.

There are also interaction considerations that your prescriber will raise. Women using oral contraceptive pills should add a barrier method for the first four weeks of Mounjaro and for four weeks after each dose increase, because tirzepatide may reduce pill absorption. HRT users should discuss whether a transdermal form is more appropriate. If you're on any other regular medicines, tell the prescribing clinician, the Mounjaro interactions page covers some common questions in this area. Anyone facing surgery should tell their anaesthetist they're on tirzepatide before any procedure.

Mounjaro is not recommended during pregnancy, when breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. If any of those situations apply, your prescriber will discuss what the appropriate next steps look like. For more detail on the medicine itself, the NHS tirzepatide page is a reliable starting point.